Drug Profile
Netupitant/palonosetron - Helsinn
Alternative Names: AKYNZEO; Akynzeo; Fosnetupitant/palonosetron; NEPA - Helsinn; NEPA-IV; Palonosetron/Fosnetupitant; Palonosetron/netupitantLatest Information Update: 25 Jan 2023
Price :
$50
*
At a glance
- Originator Helsinn
- Developer CSL Vifor; Glenmark Pharmaceuticals Ltd; Helsinn; HK inno.N; Mundipharma International; Purdue Pharma; Taiho Pharmaceutical
- Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
- Mechanism of Action Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 24 Jan 2023 Immedica in-licenses netupitant-palonosetron from Helsinn for commercialization in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein
- 23 Jan 2023 Launched for Chemotherapy-induced nausea and vomiting (Prevention) in India (IV)
- 10 Jan 2023 Phase-III clinical trials in Chemotherapy-induced nausea and vomiting (Prevention) in China (IV) before January 2023 (Helsinn pipeline, January 2023)